RG7834

Research use only, not for human use.

RG7834 is a highly selective and orally bioavailable inhibitor of HBV(HBsAg and HBeAg and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells).

RG7834 is a highly selective and orally bioavailable inhibitor of HBV(HBsAg and HBeAg and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells).

RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.RG7834 has no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or hERG channel.

RG7834 (4 mg/kg, twice daily for 21 days) shows anti-HBV efficacy in HBV-infected human liver chimeric uPA-SCID mice.RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, with a half-life of 4.9 h in mice. Animal Model:HBV-infected human liver chimeric uPA-SCID mice Dosage:4 mg/kg Administration:Twice daily for 21 days Result:Reduced both HBsAg and HBeAg, also decreased serum HBV DNA by 0.6 log10 in mice.

RO 7020322

Microbiology/Virology

HBV

HBeAg|HBsAg|HBV DNA

——

——

2072057-17-9

401.45

C22H27NO6

>98% (HPLC)

DMSO:125 mg/mL (311.37 mM; Need ultrasonic)

CC(C)[C@@H]1CC2=CC(=C(C=C2C3=CC(=O)C(=CN13)C(=O)O)OC)OCCCOC

——

(-20℃)

With Ice Pack

≥ 2 years